nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Ifosfamide—testicular cancer	0.134	0.419	CbGbCtD
Vardenafil—CYP3A5—Etoposide—testicular cancer	0.0642	0.2	CbGbCtD
Vardenafil—CYP3A4—Ifosfamide—testicular cancer	0.0524	0.163	CbGbCtD
Vardenafil—CYP3A4—Vinblastine—testicular cancer	0.0278	0.0866	CbGbCtD
Vardenafil—CYP3A4—Etoposide—testicular cancer	0.025	0.078	CbGbCtD
Vardenafil—CYP3A4—Doxorubicin—testicular cancer	0.0171	0.0532	CbGbCtD
Vardenafil—PDE11A—testis—testicular cancer	0.0122	0.12	CbGeAlD
Vardenafil—PDE6G—testis—testicular cancer	0.0118	0.116	CbGeAlD
Vardenafil—PDE1B—gonad—testicular cancer	0.0109	0.108	CbGeAlD
Vardenafil—PDE10A—female gonad—testicular cancer	0.00897	0.0882	CbGeAlD
Vardenafil—PDE6G—lymph node—testicular cancer	0.00854	0.0839	CbGeAlD
Vardenafil—PDE10A—testis—testicular cancer	0.00796	0.0782	CbGeAlD
Vardenafil—PDE1B—testis—testicular cancer	0.00788	0.0775	CbGeAlD
Vardenafil—PDE5A—gonad—testicular cancer	0.00646	0.0635	CbGeAlD
Vardenafil—PDE10A—lymph node—testicular cancer	0.00577	0.0567	CbGeAlD
Vardenafil—PDE1B—lymph node—testicular cancer	0.00572	0.0562	CbGeAlD
Vardenafil—PDE5A—female gonad—testicular cancer	0.00525	0.0516	CbGeAlD
Vardenafil—PDE5A—testis—testicular cancer	0.00466	0.0458	CbGeAlD
Vardenafil—PDE11A—G alpha (s) signalling events—INSL3—testicular cancer	0.00348	0.126	CbGpPWpGaD
Vardenafil—PDE5A—lymph node—testicular cancer	0.00337	0.0332	CbGeAlD
Vardenafil—PDE10A—G alpha (s) signalling events—INSL3—testicular cancer	0.0031	0.113	CbGpPWpGaD
Vardenafil—CYP3A5—female gonad—testicular cancer	0.00218	0.0214	CbGeAlD
Vardenafil—PDE1B—G alpha (s) signalling events—INSL3—testicular cancer	0.00157	0.057	CbGpPWpGaD
Vardenafil—Rash—Bleomycin—testicular cancer	0.00077	0.0014	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—testicular cancer	0.00077	0.0014	CcSEcCtD
Vardenafil—Pain—Cisplatin—testicular cancer	0.000769	0.0014	CcSEcCtD
Vardenafil—Dermatitis—Bleomycin—testicular cancer	0.000769	0.0014	CcSEcCtD
Vardenafil—Hypersensitivity—Ifosfamide—testicular cancer	0.000769	0.0014	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000767	0.0014	CcSEcCtD
Vardenafil—Conjunctivitis—Methotrexate—testicular cancer	0.000752	0.00137	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—testicular cancer	0.000752	0.00137	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—testicular cancer	0.000752	0.00137	CcSEcCtD
Vardenafil—Asthenia—Ifosfamide—testicular cancer	0.000749	0.00136	CcSEcCtD
Vardenafil—Sweating—Methotrexate—testicular cancer	0.000742	0.00135	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—testicular cancer	0.000742	0.00135	CcSEcCtD
Vardenafil—Feeling abnormal—Cisplatin—testicular cancer	0.000741	0.00135	CcSEcCtD
Vardenafil—Paraesthesia—Etoposide—testicular cancer	0.00074	0.00135	CcSEcCtD
Vardenafil—Pruritus—Ifosfamide—testicular cancer	0.000738	0.00134	CcSEcCtD
Vardenafil—Haematuria—Methotrexate—testicular cancer	0.000738	0.00134	CcSEcCtD
Vardenafil—Dyspnoea—Etoposide—testicular cancer	0.000735	0.00134	CcSEcCtD
Vardenafil—Somnolence—Etoposide—testicular cancer	0.000733	0.00133	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—testicular cancer	0.000732	0.00133	CcSEcCtD
Vardenafil—Hepatobiliary disease—Methotrexate—testicular cancer	0.000732	0.00133	CcSEcCtD
Vardenafil—Epistaxis—Methotrexate—testicular cancer	0.00073	0.00133	CcSEcCtD
Vardenafil—Nausea—Bleomycin—testicular cancer	0.000725	0.00132	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—testicular cancer	0.000724	0.00132	CcSEcCtD
Vardenafil—Infestation—Epirubicin—testicular cancer	0.000724	0.00132	CcSEcCtD
Vardenafil—Vomiting—Dactinomycin—testicular cancer	0.000724	0.00132	CcSEcCtD
Vardenafil—Rash—Dactinomycin—testicular cancer	0.000718	0.00131	CcSEcCtD
Vardenafil—Diarrhoea—Ifosfamide—testicular cancer	0.000714	0.0013	CcSEcCtD
Vardenafil—PDE11A—GPCR downstream signaling—INSL3—testicular cancer	0.000714	0.0259	CbGpPWpGaD
Vardenafil—Gastrointestinal disorder—Etoposide—testicular cancer	0.000712	0.00129	CcSEcCtD
Vardenafil—Pain—Etoposide—testicular cancer	0.000705	0.00128	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—testicular cancer	0.000704	0.00128	CcSEcCtD
Vardenafil—Haemoglobin—Methotrexate—testicular cancer	0.000698	0.00127	CcSEcCtD
Vardenafil—Haemorrhage—Methotrexate—testicular cancer	0.000695	0.00126	CcSEcCtD
Vardenafil—Sweating—Epirubicin—testicular cancer	0.000695	0.00126	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—testicular cancer	0.000691	0.00126	CcSEcCtD
Vardenafil—Dizziness—Ifosfamide—testicular cancer	0.00069	0.00126	CcSEcCtD
Vardenafil—Pharyngitis—Methotrexate—testicular cancer	0.00069	0.00125	CcSEcCtD
Vardenafil—Urinary tract disorder—Methotrexate—testicular cancer	0.000686	0.00125	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000686	0.00125	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—testicular cancer	0.000685	0.00125	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—testicular cancer	0.000683	0.00124	CcSEcCtD
Vardenafil—Urethral disorder—Methotrexate—testicular cancer	0.000681	0.00124	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—testicular cancer	0.00068	0.00124	CcSEcCtD
Vardenafil—Feeling abnormal—Etoposide—testicular cancer	0.000679	0.00124	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—testicular cancer	0.000676	0.00123	CcSEcCtD
Vardenafil—Gastrointestinal pain—Etoposide—testicular cancer	0.000674	0.00123	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—testicular cancer	0.00067	0.00122	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—testicular cancer	0.00067	0.00122	CcSEcCtD
Vardenafil—Visual impairment—Methotrexate—testicular cancer	0.00067	0.00122	CcSEcCtD
Vardenafil—Vomiting—Ifosfamide—testicular cancer	0.000664	0.00121	CcSEcCtD
Vardenafil—Hypersensitivity—Cisplatin—testicular cancer	0.000663	0.00121	CcSEcCtD
Vardenafil—Rash—Ifosfamide—testicular cancer	0.000658	0.0012	CcSEcCtD
Vardenafil—Dermatitis—Ifosfamide—testicular cancer	0.000657	0.0012	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—testicular cancer	0.000654	0.00119	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—testicular cancer	0.000652	0.00119	CcSEcCtD
Vardenafil—Abdominal pain—Etoposide—testicular cancer	0.000652	0.00118	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—testicular cancer	0.000652	0.00118	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—testicular cancer	0.00065	0.00118	CcSEcCtD
Vardenafil—PDE1B—Phospholipase C-mediated cascade—FGFR3—testicular cancer	0.00065	0.0236	CbGpPWpGaD
Vardenafil—Eye disorder—Methotrexate—testicular cancer	0.000649	0.00118	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—INSL3—testicular cancer	0.000648	0.0235	CbGpPWpGaD
Vardenafil—Tinnitus—Methotrexate—testicular cancer	0.000648	0.00118	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—testicular cancer	0.000647	0.00118	CcSEcCtD
Vardenafil—Asthenia—Cisplatin—testicular cancer	0.000646	0.00117	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—testicular cancer	0.000645	0.00117	CcSEcCtD
Vardenafil—Cardiac disorder—Methotrexate—testicular cancer	0.000645	0.00117	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—testicular cancer	0.000643	0.00117	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—testicular cancer	0.000642	0.00117	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—testicular cancer	0.000639	0.00116	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—testicular cancer	0.000639	0.00116	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—testicular cancer	0.000638	0.00116	CcSEcCtD
Vardenafil—PDE10A—GPCR downstream signaling—INSL3—testicular cancer	0.000636	0.0231	CbGpPWpGaD
Vardenafil—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000634	0.00115	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—testicular cancer	0.000632	0.00115	CcSEcCtD
Vardenafil—Angiopathy—Methotrexate—testicular cancer	0.000631	0.00115	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—testicular cancer	0.000629	0.00114	CcSEcCtD
Vardenafil—Immune system disorder—Methotrexate—testicular cancer	0.000628	0.00114	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—testicular cancer	0.000627	0.00114	CcSEcCtD
Vardenafil—Mediastinal disorder—Methotrexate—testicular cancer	0.000626	0.00114	CcSEcCtD
Vardenafil—Nausea—Ifosfamide—testicular cancer	0.00062	0.00113	CcSEcCtD
Vardenafil—Diarrhoea—Cisplatin—testicular cancer	0.000616	0.00112	CcSEcCtD
Vardenafil—Mental disorder—Methotrexate—testicular cancer	0.000609	0.00111	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—testicular cancer	0.000608	0.00111	CcSEcCtD
Vardenafil—Hypersensitivity—Etoposide—testicular cancer	0.000607	0.0011	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—testicular cancer	0.000606	0.0011	CcSEcCtD
Vardenafil—Erythema—Methotrexate—testicular cancer	0.000605	0.0011	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—testicular cancer	0.000605	0.0011	CcSEcCtD
Vardenafil—Flushing—Epirubicin—testicular cancer	0.000604	0.0011	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—testicular cancer	0.000604	0.0011	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—testicular cancer	0.000603	0.0011	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—testicular cancer	0.000602	0.00109	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—testicular cancer	0.000599	0.00109	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—testicular cancer	0.000597	0.00109	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—testicular cancer	0.000594	0.00108	CcSEcCtD
Vardenafil—Asthenia—Etoposide—testicular cancer	0.000591	0.00108	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—testicular cancer	0.000591	0.00108	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—testicular cancer	0.00059	0.00107	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—testicular cancer	0.00059	0.00107	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—testicular cancer	0.000587	0.00107	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—testicular cancer	0.000586	0.00107	CcSEcCtD
Vardenafil—Back pain—Methotrexate—testicular cancer	0.000585	0.00106	CcSEcCtD
Vardenafil—Pruritus—Etoposide—testicular cancer	0.000583	0.00106	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—testicular cancer	0.00058	0.00105	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—INSL3—testicular cancer	0.000578	0.021	CbGpPWpGaD
Vardenafil—Vomiting—Cisplatin—testicular cancer	0.000572	0.00104	CcSEcCtD
Vardenafil—Vision blurred—Methotrexate—testicular cancer	0.00057	0.00104	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—testicular cancer	0.00057	0.00104	CcSEcCtD
Vardenafil—Rash—Cisplatin—testicular cancer	0.000567	0.00103	CcSEcCtD
Vardenafil—Dermatitis—Cisplatin—testicular cancer	0.000567	0.00103	CcSEcCtD
Vardenafil—Erythema—Epirubicin—testicular cancer	0.000566	0.00103	CcSEcCtD
Vardenafil—Diarrhoea—Etoposide—testicular cancer	0.000564	0.00103	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—testicular cancer	0.000562	0.00102	CcSEcCtD
Vardenafil—Ill-defined disorder—Methotrexate—testicular cancer	0.000561	0.00102	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—testicular cancer	0.000561	0.00102	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—testicular cancer	0.000558	0.00102	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—testicular cancer	0.000558	0.00102	CcSEcCtD
Vardenafil—Back pain—Epirubicin—testicular cancer	0.000548	0.000996	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—testicular cancer	0.000546	0.000993	CcSEcCtD
Vardenafil—Malaise—Methotrexate—testicular cancer	0.000546	0.000992	CcSEcCtD
Vardenafil—Dizziness—Etoposide—testicular cancer	0.000545	0.000991	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—testicular cancer	0.000544	0.00099	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—testicular cancer	0.000544	0.000988	CcSEcCtD
Vardenafil—Vertigo—Methotrexate—testicular cancer	0.000544	0.000988	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—testicular cancer	0.000542	0.000986	CcSEcCtD
Vardenafil—Nausea—Cisplatin—testicular cancer	0.000534	0.000972	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—testicular cancer	0.000534	0.00097	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—testicular cancer	0.000527	0.000959	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—testicular cancer	0.000525	0.000955	CcSEcCtD
Vardenafil—Convulsion—Methotrexate—testicular cancer	0.000524	0.000953	CcSEcCtD
Vardenafil—Vomiting—Etoposide—testicular cancer	0.000524	0.000953	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—testicular cancer	0.000524	0.000953	CcSEcCtD
Vardenafil—Rash—Etoposide—testicular cancer	0.00052	0.000945	CcSEcCtD
Vardenafil—Dermatitis—Etoposide—testicular cancer	0.000519	0.000944	CcSEcCtD
Vardenafil—Headache—Etoposide—testicular cancer	0.000516	0.000939	CcSEcCtD
Vardenafil—Arthralgia—Methotrexate—testicular cancer	0.000515	0.000937	CcSEcCtD
Vardenafil—Chest pain—Methotrexate—testicular cancer	0.000515	0.000937	CcSEcCtD
Vardenafil—Myalgia—Methotrexate—testicular cancer	0.000515	0.000937	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000511	0.00093	CcSEcCtD
Vardenafil—Malaise—Epirubicin—testicular cancer	0.000511	0.000928	CcSEcCtD
Vardenafil—Discomfort—Methotrexate—testicular cancer	0.000509	0.000925	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—testicular cancer	0.000509	0.000925	CcSEcCtD
Vardenafil—Syncope—Epirubicin—testicular cancer	0.000508	0.000923	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—testicular cancer	0.000507	0.000921	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—testicular cancer	0.000504	0.000916	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—testicular cancer	0.0005	0.00091	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—testicular cancer	0.000498	0.000905	CcSEcCtD
Vardenafil—Anaphylactic shock—Methotrexate—testicular cancer	0.000494	0.000898	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—testicular cancer	0.000494	0.000898	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—testicular cancer	0.000491	0.000892	CcSEcCtD
Vardenafil—Infection—Methotrexate—testicular cancer	0.00049	0.000892	CcSEcCtD
Vardenafil—Nausea—Etoposide—testicular cancer	0.00049	0.00089	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—testicular cancer	0.000486	0.000884	CcSEcCtD
Vardenafil—Nervous system disorder—Methotrexate—testicular cancer	0.000484	0.000881	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—testicular cancer	0.000482	0.000877	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—testicular cancer	0.000482	0.000877	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—testicular cancer	0.000482	0.000877	CcSEcCtD
Vardenafil—PDE6G—Signaling by Wnt—H2AFZ—testicular cancer	0.000481	0.0174	CbGpPWpGaD
Vardenafil—Anxiety—Epirubicin—testicular cancer	0.00048	0.000873	CcSEcCtD
Vardenafil—Skin disorder—Methotrexate—testicular cancer	0.00048	0.000872	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000479	0.00087	CcSEcCtD
Vardenafil—Hyperhidrosis—Methotrexate—testicular cancer	0.000477	0.000868	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—testicular cancer	0.000476	0.000866	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—testicular cancer	0.000472	0.000859	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—testicular cancer	0.000471	0.000857	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—testicular cancer	0.000471	0.000856	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—testicular cancer	0.00047	0.000854	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—testicular cancer	0.000463	0.000842	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—testicular cancer	0.000462	0.00084	CcSEcCtD
Vardenafil—Hypotension—Methotrexate—testicular cancer	0.000461	0.000839	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—testicular cancer	0.00046	0.000837	CcSEcCtD
Vardenafil—Infection—Epirubicin—testicular cancer	0.000459	0.000835	CcSEcCtD
Vardenafil—Shock—Epirubicin—testicular cancer	0.000455	0.000827	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—testicular cancer	0.000454	0.000825	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—testicular cancer	0.000453	0.000824	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—testicular cancer	0.000451	0.00082	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00045	0.000818	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—testicular cancer	0.000449	0.000816	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—testicular cancer	0.000447	0.000812	CcSEcCtD
Vardenafil—Insomnia—Methotrexate—testicular cancer	0.000447	0.000812	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—testicular cancer	0.000446	0.000811	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—testicular cancer	0.000446	0.000811	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—testicular cancer	0.000446	0.000811	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—testicular cancer	0.000444	0.000808	CcSEcCtD
Vardenafil—Paraesthesia—Methotrexate—testicular cancer	0.000443	0.000806	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000443	0.000805	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—testicular cancer	0.000441	0.000801	CcSEcCtD
Vardenafil—Dyspnoea—Methotrexate—testicular cancer	0.00044	0.0008	CcSEcCtD
Vardenafil—Somnolence—Methotrexate—testicular cancer	0.000439	0.000798	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—testicular cancer	0.000436	0.000793	CcSEcCtD
Vardenafil—Dyspepsia—Methotrexate—testicular cancer	0.000435	0.00079	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—testicular cancer	0.000432	0.000785	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—testicular cancer	0.000428	0.000777	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000426	0.000775	CcSEcCtD
Vardenafil—Infection—Doxorubicin—testicular cancer	0.000425	0.000772	CcSEcCtD
Vardenafil—Pain—Methotrexate—testicular cancer	0.000422	0.000768	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000421	0.000766	CcSEcCtD
Vardenafil—Shock—Doxorubicin—testicular cancer	0.000421	0.000765	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—testicular cancer	0.000419	0.000762	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—testicular cancer	0.000418	0.00076	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—testicular cancer	0.000417	0.000759	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—testicular cancer	0.000415	0.000755	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—testicular cancer	0.000415	0.000754	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—testicular cancer	0.000413	0.000752	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—testicular cancer	0.000412	0.000749	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—testicular cancer	0.000411	0.000747	CcSEcCtD
Vardenafil—Feeling abnormal—Methotrexate—testicular cancer	0.000407	0.00074	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—testicular cancer	0.000407	0.00074	CcSEcCtD
Vardenafil—Gastrointestinal pain—Methotrexate—testicular cancer	0.000404	0.000734	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.0004	0.0145	CbGpPWpGaD
Vardenafil—Hypotension—Doxorubicin—testicular cancer	0.000399	0.000726	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000399	0.000725	CcSEcCtD
Vardenafil—Pain—Epirubicin—testicular cancer	0.000395	0.000719	CcSEcCtD
Vardenafil—Abdominal pain—Methotrexate—testicular cancer	0.00039	0.00071	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00039	0.000708	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—testicular cancer	0.000387	0.000703	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—testicular cancer	0.000384	0.000698	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—INSL3—testicular cancer	0.000383	0.0139	CbGpPWpGaD
Vardenafil—Dyspnoea—Doxorubicin—testicular cancer	0.000381	0.000693	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—testicular cancer	0.000381	0.000692	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—testicular cancer	0.00038	0.000691	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—testicular cancer	0.000378	0.000687	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—testicular cancer	0.000376	0.000684	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—KITLG—testicular cancer	0.000376	0.0136	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—KITLG—testicular cancer	0.000374	0.0136	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—KITLG—testicular cancer	0.000372	0.0135	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KITLG—testicular cancer	0.00037	0.0134	CbGpPWpGaD
Vardenafil—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000369	0.000671	CcSEcCtD
Vardenafil—Pain—Doxorubicin—testicular cancer	0.000366	0.000665	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—testicular cancer	0.000365	0.000664	CcSEcCtD
Vardenafil—Hypersensitivity—Methotrexate—testicular cancer	0.000364	0.000662	CcSEcCtD
Vardenafil—Asthenia—Methotrexate—testicular cancer	0.000354	0.000644	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—testicular cancer	0.000352	0.000641	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—INSL3—testicular cancer	0.00035	0.0127	CbGpPWpGaD
Vardenafil—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00035	0.000636	CcSEcCtD
Vardenafil—Pruritus—Methotrexate—testicular cancer	0.000349	0.000635	CcSEcCtD
Vardenafil—PDE1B—DAP12 interactions—KITLG—testicular cancer	0.000348	0.0126	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KITLG—testicular cancer	0.000348	0.0126	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—KITLG—testicular cancer	0.000345	0.0125	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000342	0.0124	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—INSL3—testicular cancer	0.000341	0.0124	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KITLG—testicular cancer	0.000341	0.0124	CbGpPWpGaD
Vardenafil—Hypersensitivity—Epirubicin—testicular cancer	0.00034	0.000619	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—testicular cancer	0.000338	0.000615	CcSEcCtD
Vardenafil—Diarrhoea—Methotrexate—testicular cancer	0.000338	0.000614	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—testicular cancer	0.000332	0.000603	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—testicular cancer	0.000327	0.000594	CcSEcCtD
Vardenafil—Dizziness—Methotrexate—testicular cancer	0.000326	0.000594	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—INSL3—testicular cancer	0.000322	0.0117	CbGpPWpGaD
Vardenafil—Diarrhoea—Epirubicin—testicular cancer	0.000316	0.000575	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—testicular cancer	0.000315	0.000573	CcSEcCtD
Vardenafil—Vomiting—Methotrexate—testicular cancer	0.000314	0.000571	CcSEcCtD
Vardenafil—Rash—Methotrexate—testicular cancer	0.000311	0.000566	CcSEcCtD
Vardenafil—Dermatitis—Methotrexate—testicular cancer	0.000311	0.000566	CcSEcCtD
Vardenafil—Headache—Methotrexate—testicular cancer	0.000309	0.000562	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000308	0.0112	CbGpPWpGaD
Vardenafil—Asthenia—Doxorubicin—testicular cancer	0.000307	0.000558	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—testicular cancer	0.000306	0.000556	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—testicular cancer	0.000302	0.00055	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000297	0.0108	CbGpPWpGaD
Vardenafil—Vomiting—Epirubicin—testicular cancer	0.000294	0.000534	CcSEcCtD
Vardenafil—Nausea—Methotrexate—testicular cancer	0.000293	0.000533	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—INSL3—testicular cancer	0.000293	0.0106	CbGpPWpGaD
Vardenafil—Diarrhoea—Doxorubicin—testicular cancer	0.000293	0.000532	CcSEcCtD
Vardenafil—Rash—Epirubicin—testicular cancer	0.000291	0.00053	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—testicular cancer	0.000291	0.000529	CcSEcCtD
Vardenafil—Headache—Epirubicin—testicular cancer	0.000289	0.000526	CcSEcCtD
Vardenafil—Dizziness—Doxorubicin—testicular cancer	0.000283	0.000514	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—FGFR3—testicular cancer	0.000279	0.0101	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—FGFR3—testicular cancer	0.000278	0.0101	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—FGFR3—testicular cancer	0.000276	0.01	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—FGFR3—testicular cancer	0.000275	0.00998	CbGpPWpGaD
Vardenafil—Nausea—Epirubicin—testicular cancer	0.000274	0.000499	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000273	0.0099	CbGpPWpGaD
Vardenafil—Vomiting—Doxorubicin—testicular cancer	0.000272	0.000494	CcSEcCtD
Vardenafil—Rash—Doxorubicin—testicular cancer	0.00027	0.00049	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—testicular cancer	0.000269	0.00049	CcSEcCtD
Vardenafil—Headache—Doxorubicin—testicular cancer	0.000268	0.000487	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000259	0.00939	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—FGFR3—testicular cancer	0.000259	0.00939	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—FGFR3—testicular cancer	0.000256	0.00931	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—KIT—testicular cancer	0.000256	0.0093	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—KIT—testicular cancer	0.000255	0.00926	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000254	0.00923	CbGpPWpGaD
Vardenafil—Nausea—Doxorubicin—testicular cancer	0.000254	0.000462	CcSEcCtD
Vardenafil—PDE1B—Signaling by ERBB2—KIT—testicular cancer	0.000254	0.00921	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—FGFR3—testicular cancer	0.000253	0.00918	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KIT—testicular cancer	0.000253	0.00917	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KIT—testicular cancer	0.000238	0.00862	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—KIT—testicular cancer	0.000238	0.00862	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KITLG—testicular cancer	0.000237	0.00861	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—KIT—testicular cancer	0.000235	0.00855	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000233	0.00847	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KIT—testicular cancer	0.000232	0.00843	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000229	0.00832	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—BCL10—testicular cancer	0.000224	0.00814	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—HPGDS—testicular cancer	0.000211	0.00766	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00021	0.00764	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—FGFR3—testicular cancer	0.000176	0.0064	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—INSL3—testicular cancer	0.000173	0.00628	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KIT—testicular cancer	0.000162	0.00587	CbGpPWpGaD
Vardenafil—PDE6G—Disease—H2AFZ—testicular cancer	0.00016	0.00581	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KITLG—testicular cancer	0.000147	0.00535	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KITLG—testicular cancer	0.000135	0.00491	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—BCL10—testicular cancer	0.000131	0.00474	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—H2AFZ—testicular cancer	0.000123	0.00445	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—STK11—testicular cancer	0.000122	0.00442	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KITLG—testicular cancer	0.000113	0.00409	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—H2AFZ—testicular cancer	0.000112	0.00407	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—STK11—testicular cancer	0.000111	0.00405	CbGpPWpGaD
Vardenafil—PDE6G—Disease—FGFR3—testicular cancer	0.000109	0.00397	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—H2AFZ—testicular cancer	0.000109	0.00397	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—STK11—testicular cancer	0.000109	0.00394	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KITLG—testicular cancer	0.000103	0.00374	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—FGFR3—testicular cancer	0.000101	0.00365	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KITLG—testicular cancer	0.000101	0.00365	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KIT—testicular cancer	0.000101	0.00365	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.81e-05	0.00356	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KIT—testicular cancer	9.23e-05	0.00335	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—FGFR3—testicular cancer	8.38e-05	0.00304	CbGpPWpGaD
Vardenafil—PDE1B—Disease—H2AFZ—testicular cancer	7.91e-05	0.00287	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KITLG—testicular cancer	7.88e-05	0.00286	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KIT—testicular cancer	7.7e-05	0.00279	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FGFR3—testicular cancer	7.67e-05	0.00278	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FGFR3—testicular cancer	7.47e-05	0.00271	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KITLG—testicular cancer	7.27e-05	0.00264	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KIT—testicular cancer	7.04e-05	0.00255	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KIT—testicular cancer	6.86e-05	0.00249	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FGFR3—testicular cancer	5.86e-05	0.00213	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—H2AFZ—testicular cancer	5.54e-05	0.00201	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STK11—testicular cancer	5.51e-05	0.002	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FGFR3—testicular cancer	5.41e-05	0.00196	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KIT—testicular cancer	5.38e-05	0.00195	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KITLG—testicular cancer	5.09e-05	0.00185	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KIT—testicular cancer	4.96e-05	0.0018	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FGFR3—testicular cancer	3.79e-05	0.00137	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—HPGDS—testicular cancer	3.61e-05	0.00131	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KIT—testicular cancer	3.48e-05	0.00126	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—STK11—testicular cancer	2.62e-05	0.000952	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HPGDS—testicular cancer	1.68e-05	0.000609	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—STK11—testicular cancer	1.22e-05	0.000442	CbGpPWpGaD
